RRRamzy H. Rimawi

Ramzy H. Rimawi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ramzy H. Rimawi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hunting For Tularaemia – A Review of Cases in North Carolina

    by R. H. Rimawi, K. B. Shah, R. A. Chowdhary, P. P. Cook

    Human infections with Francisella tularensis can be acquired via numerous routes, including ingestion, inhalation, arthropod bite or direct contact with infected animals. Since 1991, there have been 25 reported cases of tularaemia in North Carolina, most of which were associated with rabbit hunting or cat bites. We present two adults cases of pulmonary and oropharyngeal tularaemia and review the reported cases since 1991-2013. We also present the fifth case of pulmonary empyema. While cavitary pneumonias are primarily treated with drainage, we illustrate a case of cavitary pneumonia associated with tularaemia successfully treated with oral ciprofloxacin after drainage. Tularaemia should be considered in patients with a perplexing radiographic image, animal exposure and lack of response to conventional empiric broad-spectrum antibiotics. Even in serious cases of pneumonic tularaemia, fluoroquinolones may provide a suitable alternative to aminoglycosides.


  • Risk of redocumenting penicillin allergy in a cohort of patients with negative penicillin skin tests

    by Ramzy H. Rimawi, Kaushal B. Shah, Paul P. Cook

    BACKGROUND: Even though electronic documentation of allergies is critical to patient safety, inaccuracies in documentation can potentiate serious problems. Prior studies have not evaluated factors associated with redocumenting penicillin allergy in the medical record despite a proven tolerance with a penicillin skin test (PST).OBJECTIVE: Assess the prevalence of reinstating inaccurate allergy information and associated factors thereof.DESIGN: We conducted a retrospective observational study from August 1, 2012 to July 31, 2013 of patients who previously had a negative PST. We reviewed records from the hospital, long‐term care facilities (LTCF), and primary doctors' offices.SETTING: Vidant Health, a system of 10 hospitals in North Carolina.SUBJECTS: Patients with proven penicillin tolerance rehospitalized within a year period from the PST.MEASUREMENTS: We gauged hospital reappearances, penicillin allergy redocumentation, residence, antimicrobial use, and presence of dementia or altered mentation.RESULTS: Of the 150 patients with negative PST, 55 (37%) revisited a Vidant system hospital within a 1‐year period, of whom 21 were LTCF residents. Twenty (36%) of the 55 patients had penicillin allergy redocumented without apparent reason. Factors associated with penicillin allergy redocumentation included age >65 years (P = 0.011), LTCF residence (P = 0.0001), acutely altered mentation (P < 0.0001), and dementia (P < 0.0001). Penicillin allergy was still listed in all 21 (100%) of the LTCF records.CONCLUSIONS: At our hospital system, penicillin allergies are often redocumented into the medical record despite proven tolerance. The benefits of PST may be limited by inadequately removing the allergy from different electronic/paper hospital, LTCF, primary physician, and community pharmacy records. Journal of Hospital Medicine 2013;8:615–618. © 2013 Society of Hospital Medicine


  • Impact of Regular Collaboration Between Infectious Diseases and Critical Care Practitioners on Antimicrobial Utilization and Patient Outcome*

    by Ramzy H. Rimawi, Mark A. Mazer, Dawd S. Siraj, Mike Gooch, Paul P. Cook

    Antimicrobial stewardship programs have been shown to help reduce the use of unnecessary antimicrobial agents in the hospital setting. To date, there has been very little data focusing on high-use areas, such as the medical ICU. A prospective intervention was done to assess guideline compliance, antimicrobial expenditure, and healthcare cost when an infectious disease fellow interacts regularly with the medical ICU team. A 3-month retrospective chart review was followed by a 3-month prospective intervention the following year. Two hundred forty-six total charts were reviewed to assess generally accepted guideline compliance, demographics, and microbiologic results. Twenty-four-bed medical ICU at an 861-bed tertiary care, university teaching hospital in North Carolina. Patients receiving antibiotics in the medical ICU. During the intervention period, the infectious disease fellow reviewed the charts, including physician notes and microbiology data, and discussed antimicrobial use with the medical ICU team. Antimicrobial use, treatment duration, Acute Physiology and Chronic Health Evaluation II scores, length of stay, mechanical ventilation days, and mortality rates were compared during the two periods. No baseline statistically significant differences in the two groups were noted (i.e., age, gender, race, or Acute Physiology and Chronic Healthcare Evaluation II scores). Indications for antibiotics included healthcare-associated (53%) and community-acquired pneumonias (17%). Significant reductions were seen in extended-spectrum penicillins (p = 0.0080), carbapenems (p = 0.0013), vancomycin (p = 0.0040), and metronidazole (p = 0.0004) following the intervention. Antimicrobial modification led to an increase in narrow-spectrum penicillins (p = 0.0322). The intervention group had a significantly lower rate of treatments that did not correspond to guidelines (p < 0.0001). There was a reduction in mechanical ventilation days (p = 0.0053), length of stay (p = 0.0188), and hospital mortality (p = 0.0367). The annual calculated healthcare savings was $89,944 in early antibiotic cessation alone. Active communication with an infectious disease practitioner can significantly reduce medical ICU antibiotic overuse by earlier modification or cessation of antibiotics without increasing mortality. This in turn can reduce healthcare costs, foster prodigious education, and strengthen relations between the subspecialties.


  • Ceftaroline - a cause for neutropenia

    by R. H. Rimawi, A. Frenkel, P. P. Cook

    The US Food and Drug Administration approved ceftaroline in 2010 for the treatment of community-acquired pneumonia and skin and soft-tissue infections. The most common adverse reactions are diarrhoea, nausea and rash. To present the first case of neutropenia directly related to ceftaroline. A 90-year-old female was given ceftaroline for treatment of a pneumonia complicated by methicillin-resistant Staphylococcus aureus bacteraemia and possible vertebral osteomyelitis. After 25 days of ceftaroline, she developed neutropenia. Ceftaroline was discontinued and her white blood cell count returned to normal within one week. Although neutropenia is a potential cephalosporin class effect, we present the first case of neutropenia directly related to ceftaroline. Agranulocytosis and neutropenia are rare, yet potentially life-threatening adverse effects of cephalosporins. Healthcare providers should be aware of the potential for ceftaroline to cause neutropenia, particularly in patients treated for greater than two weeks.


  • The impact of penicillin skin testing on clinical practice and antimicrobial stewardship

    by Ramzy H. Rimawi, Paul P. Cook, Michael Gooch, Badih Kabchi, Muhammad S. Ashraf, Bassam H. Rimawi, Mulugeta Gebregziabher, Dawd S. Siraj

    BACKGROUND: Penicillin skin testing (PST) is a simple and reliable way of diagnosing penicillin allergy. After being off the market for 4 years, penicilloyl‐polylysine was reintroduced in 2009 as PRE‐PEN. We describe the negative predictive value (NPV) of PST and the impact on antibiotic selection in a sample of hospitalized patients with a reported history of penicillin allergy.METHODS: We introduced a quality improvement process at our 861‐bed tertiary care hospital that used PST to guide antibiotic usage in patients with a history consistent with an immunoglobulin E (IgE)‐mediated reaction to penicillin. Subjects with a negative PST were then transitioned to a β‐lactam agent for the remainder of their therapy. NPV of skin testing was established at 24‐hour follow‐up. We are reporting the result of 146 patients tested between March 2012 and July 2012.RESULTS: A total of 146 patients with a history of penicillin allergy and negative PST were treated with β‐lactam antibiotics. Of these, only 1 subject experienced an allergic reaction to the PST. The remaining 145 patients tolerated a full course of β‐lactam therapy without an allergic response, giving the PST a 100% NPV. We estimated that PST‐guided antibiotic alteration for these patients resulted in an estimated annual savings of $82,000.CONCLUSION: Patients with a history of penicillin allergy who have a negative PST result are at a low risk of developing an immediate‐type hypersensitivity reaction to β‐lactam antibiotics. The increased use of PST may help improve antibiotic stewardship in the hospital setting. Journal of Hospital Medicine 2013;8:341–345. © 2013 Society of Hospital Medicine